MTPConnect is guided by an experienced Board of Directors.
The Board of Directors
Sue MacLeman – Chair
Sue MacLeman has more than 30 years experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector. Sue is currently the Chair of MTPConnect (MTPII-GC Ltd), Chair of Oventus Medical Ltd (ASX:OVN), Non-Executive Director of Anatara Lifesciences Ltd (ASX:ANR), Chair of TALi Digital Ltd (ASX:TDI), and Non-Executive Director of Palla Pharma Ltd (ASX:PAL), Planet Innovation and Omico. Sue is also appointed to several academic and government advisory committees, including the CSIRO Health and Biosecurity Advisory Committee, the Prime Minister’s Digital Experts Advisory Committee, DMTC’s Medical Countermeasures and various COVID-19 taskforces. Her broad commercial experience is underpinned by graduate qualifications in pharmacy and postgraduate qualifications in corporate governance, commercial law, business administration and marketing. Sue is a Fellow and Chair Health Forum ATSE, Chair Policy Forum ATSE, Fellow ACPP and Fellow/Graduate of AICD. In 2019, Sue was awarded the prestigious AusBiotech and Johnson & Johnson Innovation Industry Leadership Award in recognition of her outstanding contribution to the MTP sector.
Dr Dan Grant - Managing Director & Chief Executive Officer
Dr Dan Grant has spent more than 25 years in senior roles in the pharmaceutical, higher education and medical research sectors. Prior to joining MTPConnect in 2018, Dr Grant was the inaugural Pro Vice-Chancellor for Industry Engagement at La Trobe University where he had oversight of the university's innovation, commercialisation and industry engagement activities. He was also the Senior Director and Head of Pfizer's External Research and Development Innovation group for ANZ/Singapore and their head of open innovation. Dan also sits on the Expert Advisory Panel for the Stem Cell Mission. He has a PhD in Cardiovascular Physiology and an MBA.
Dr Nicholas Cerneaz – Director
Dr Cerneaz has been building companies to commercialise academic research for more than two decades. After gaining a DPhil from Oxford University in the early 90s in mammography technologies assisting the management of breast cancer, he has worked extensively guiding and advising the development of a number of medical technology startup companies, covering a variety of fields including radiology, oncology, ophthalmology, pathology and immunology. Other industrial experience includes automation and process optimisation in heavy manufacturing and process industries, astronomy instrumentation design and implementation, and advanced computer vision safety systems for the automotive industry. With MyHealthTest Pty Ltd, a Canberra based MedTech startup, he worked to bring convenient pathology services to consumers with do-it-yourself (at home) sample collection and test results delivered online to both patient and doctor. Dr Cerneaz has also previously been a director of various NFP and AIM-listed companies.
Alex Fowkes - Non-Executive Director
Alex Fowkes was the Chief Strategy Officer for WuXi NextCODE, based in Singapore. As a life science executive, he is an experienced leader and thought partner for life science strategy, commercial operations and business development. He has extensive experience in leading strategy development and operational improvement projects within the pharmaceutical, contract research and bioinformatics industries with a core expertise in the strategy, execution and management of strategic partnerships. His specialities are life science strategy & operations, business development and strategic transactions.
Julie Phillips – Director
Julie Phillips has a strong background in the biotechnology and pharmaceutical industry, having worked as the CEO and Director of start-up Australian biotechnology companies operating in the life sciences sector. Her technical background is in clinical trials, regulatory affairs and pharmacoeconomic assessment/pricing of therapeutics. From 2014-2020, Ms Phillips was Chair of AusBiotech Ltd, the peak biotechnology industry association in Australia. She is CEO and Director of BioDiem Ltd and its subsidiary, Opal Biosciences Ltd. She is also a member of the Council of the University of Newcastle, chairs Innovation and Science Australia’s R&D Incentive Committee, and sits on various government committees.
Dr Douglas Robertson – Director
Dr Robertson is the Director of Research Services at The Australian National University and has over 30 years experience in research, economic development, technology transfer, spin-out companies and commercialisation in the UK and Australia. During that time he has negotiated over $3bn of research funding, served on the boards of over 20 technology companies and assisted the establishment of over 20 other early-stage technology businesses. Dr Robertson was a founding Director of PraxisUnico (formerly Praxis), a major UK and international technology transfer and training association, from 2003-2013 and Chair in 2012 and 2013. Dr Robertson serves on the boards of four NCRIS facilities.